Litcius/Paper detail

Precision therapeutics for inflammatory bowel disease: advancing ROS-responsive nanoparticles for targeted and multifunctional drug delivery

Xiuping Wan, Caijie Zhang, Pengyu Lei, Hanbing Wang, Rongbing Chen, Qinsi Yang, Yijing Cheng, Wei Wu, Da Sun, Xiaofei Hong

2025Journal of Materials Chemistry B37 citationsDOI

Abstract

, superoxide dismutase, glutathione peroxidase, and glutathione reductase) is reduced at the site of intestinal inflammation, leading to the accumulation of reactive oxygen species (ROS). This accumulation damages the intestinal mucosa, disrupts tight junctions between cells, and compromises the integrity of the intestinal barrier, exacerbating IBD symptoms. Therefore, nanoparticles responsive to ROS and capable of mimicking antioxidant enzyme activity, such as boronates, polydopamine, sulfides, and metal nanozymes, have emerged as promising tools. These nanoparticles can respond to elevated ROS levels in inflamed intestinal regions and release drugs to effectively neutralize ROS, making them ideal candidates for IBD treatment. This review discusses the application of various ROS-responsive nanomaterial delivery systems in IBD therapy, highlights current challenges, and outlines future research directions. Furthermore, we explore the "layered programmable delivery" strategy, which combines ROS-responsive nanoparticles with pH-responsive and cell membrane-targeted nanoparticles. This strategy has the potential to overcome the limitations of single-mechanism targeted drug delivery, enabling multi-range and multi-functional treatment approaches that significantly enhance delivery efficiency, providing new insights for the future of localized IBD treatment.

Topics & Concepts

Drug deliveryInflammatory bowel diseaseDrugTargeted drug deliveryNanotechnologyInflammatory Bowel DiseasesNanoparticleMaterials scienceMedicinePharmacologyDiseaseInternal medicineAdvanced Nanomaterials in CatalysisNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranostics
Precision therapeutics for inflammatory bowel disease: advancing ROS-responsive nanoparticles for targeted and multifunctional drug delivery | Litcius